ATE206308T1 - Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid - Google Patents

Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid

Info

Publication number
ATE206308T1
ATE206308T1 AT94907963T AT94907963T ATE206308T1 AT E206308 T1 ATE206308 T1 AT E206308T1 AT 94907963 T AT94907963 T AT 94907963T AT 94907963 T AT94907963 T AT 94907963T AT E206308 T1 ATE206308 T1 AT E206308T1
Authority
AT
Austria
Prior art keywords
bpi
surfactant
compositions containing
bactericidal
medicinal compositions
Prior art date
Application number
AT94907963T
Other languages
English (en)
Inventor
Weldon Courtney Mcgregor
James Stubstad
Paul Chang
Original Assignee
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd filed Critical Xoma Technology Ltd
Application granted granted Critical
Publication of ATE206308T1 publication Critical patent/ATE206308T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT94907963T 1993-02-02 1994-02-02 Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid ATE206308T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1236093A 1993-02-02 1993-02-02
PCT/US1994/001239 WO1994017819A1 (en) 1993-02-02 1994-02-02 Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant

Publications (1)

Publication Number Publication Date
ATE206308T1 true ATE206308T1 (de) 2001-10-15

Family

ID=21754603

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94907963T ATE206308T1 (de) 1993-02-02 1994-02-02 Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid

Country Status (12)

Country Link
US (5) US5488034A (de)
EP (1) EP0682524B1 (de)
JP (2) JP3946246B2 (de)
CN (1) CN1163264C (de)
AT (1) ATE206308T1 (de)
AU (1) AU695125B2 (de)
CA (1) CA2155005C (de)
DE (1) DE69428521T2 (de)
DK (1) DK0682524T3 (de)
ES (1) ES2164098T3 (de)
PT (1) PT682524E (de)
WO (1) WO1994017819A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
JP3946246B2 (ja) * 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性／浸透性増大タンパク質（Ｂａｃｔｅｒｉｃｉｄａｌ／Ｐｅｒｍｅａｂｉｌｉｔｙ Ｉｎｃｒｅａｓｉｎｇ ｐｒｏｔｅｉｎ：ＢＰＩ）及び界面活性剤を含有する医薬組成物
US5858974A (en) * 1995-07-20 1999-01-12 Xoma Corporation Anti-fungal peptides
US6214789B1 (en) 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
WO1995000641A1 (en) 1993-06-17 1995-01-05 Xoma Corporation Lipopolysaccharide binding protein derivatives
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
DE69430823T2 (de) * 1993-09-22 2003-02-20 Xoma Technology Ltd., Berkeley Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
DE69526216T2 (de) * 1994-01-14 2002-11-14 Xoma Technology Ltd., Berkeley Antifungaleverfahren und mitteln
PT754050E (pt) * 1994-01-14 2002-11-29 Xoma Technology Ltd Metodos e materiais contra bacterias gram-positivas
US5447913A (en) 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5830860A (en) * 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
WO1997017990A1 (en) * 1995-11-14 1997-05-22 Xoma Corporation Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury
US5741779A (en) 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
JP2000510845A (ja) * 1996-05-10 2000-08-22 ゾーマ コーポレイション ヒト髄膜炎菌血症のためのｂｐｉタンパク質産物の治療用途
JP2000511190A (ja) * 1996-05-23 2000-08-29 ゾーマ コーポレイション 外傷に起因する出血に見舞われたヒトにおけるｂｐｉタンパク質産物の治療用途
EP0939766A2 (de) 1996-05-24 1999-09-08 The Regents Of The University Of Minnesota Synthese von löslichen beta-sheet bildenden peptiden
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6054492A (en) * 1996-09-09 2000-04-25 Supratek Pharma Inc. Fluorinated copolymeric pharmaceutical adjuncts
EP1304118A3 (de) * 1996-11-01 2004-01-14 XOMA Technology Ltd. Therapeutische Verwendung von BPI Proteineprodukten
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
FR2764800B1 (fr) * 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US5990082A (en) * 1997-10-22 1999-11-23 Xoma Corporation Uses of lipopolysaccharide binding protein
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
AU779281B2 (en) * 1999-04-21 2005-01-13 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Uteroglobin in the treatment of IgA mediated autoimmune disorders
US6413537B1 (en) 2000-03-10 2002-07-02 Wisconsin Alumni Research Foundation Nystatin formulation having reduced toxicity
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
CN1604788B (zh) * 2001-10-16 2013-04-17 里克斯金蒂克斯公司 高浓度蛋白制剂及其制备方法
WO2003070751A2 (en) 2002-02-20 2003-08-28 Regents Of The University Of Minnesota Partial peptide mimetics and methods
US20050276823A1 (en) * 2002-07-12 2005-12-15 Cini John K Methods and compositions for preventing oxidative degradation of proteins
JP2006504772A (ja) * 2002-10-29 2006-02-09 アルザ・コーポレーション 安定化された固体ポリペプチド粒子
ATE480258T1 (de) * 2002-11-26 2010-09-15 Eurocine Vaccines Ab Neue adjuvant auf der basis von aminen
CA2517310C (en) * 2003-02-28 2015-11-24 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations comprising a poloxamer
MXPA05010635A (es) * 2003-04-02 2005-12-12 Ares Trading Sa Formulaciones farmaceuticas liquidas de hormona estimulante de foliculos y hormona luteinizante junto con un surfactante no ionico.
US7838721B2 (en) * 2003-04-09 2010-11-23 Paragon Trade Brands, Llc Disposable articles using high column AUL superabsorbents
WO2004112826A1 (en) * 2003-06-20 2004-12-29 Ares Trading Sa Freeze-dried fsh / lh formulations
US8377459B2 (en) * 2003-07-09 2013-02-19 The Procter & Gamble Company Composition for wet wipes that enhances the efficacy of cleansing while being gentle to the skin
WO2005034999A2 (en) * 2003-10-10 2005-04-21 Bvm Holding Co. Composition comprising association complex of a pharmaceutical and a poloxamer
US7150995B2 (en) * 2004-01-16 2006-12-19 Metrika, Inc. Methods and systems for point of care bodily fluid analysis
DK1776137T3 (en) * 2004-08-04 2015-01-05 Ipsen Biopharm Ltd A pharmaceutical composition comprising botulinum neurotoxin A2
US20080102090A1 (en) * 2004-08-04 2008-05-01 Naveed Panjwani Pharmaceutical Compositon Containing Botulinum Neurotoxin A2
US20060173428A1 (en) * 2005-02-02 2006-08-03 Acors Deanna M Absorbent article with logically correlated image and textual graphics
AU2006247188A1 (en) 2005-05-18 2006-11-23 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against chlamydia infection
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
WO2009021173A1 (en) * 2007-08-08 2009-02-12 Advanced Liquid Logic, Inc. Use of additives for enhancing droplet operations
WO2009034958A1 (ja) * 2007-09-12 2009-03-19 Jsr Corporation タンパク安定化剤およびその製造方法、タンパク安定化剤の使用方法、ならびにタンパク安定化方法
PT2310412T (pt) 2008-06-20 2018-05-28 Novartis Ag Imunoglobulinas com agregação reduzida
EP2437785B1 (de) 2009-06-04 2015-02-25 Novartis AG Verfahren zur identifizierung von stellen für igg-konjugation
ES2758827T3 (es) * 2009-06-17 2020-05-06 Biomarin Pharm Inc Formulaciones para enzimas lisosómicas
CN104857504A (zh) 2010-06-25 2015-08-26 夏尔人类遗传性治疗公司 芳基硫酸酯酶a cns递送的方法和组合物
MX354016B (es) 2010-09-15 2018-02-07 J Mrsny Randall Sistemas y metodos de suministro de agentes bioactivos mediante el uso de secuencias transportadoras derivadas de toxinas.
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
GB201116271D0 (en) * 2011-09-21 2011-11-02 Univ Cardiff Dispersion anaesthetic device
EP3139965B1 (de) 2014-05-07 2021-09-29 Applied Molecular Transport Inc. Von cholixtoxin abgeleitete fusionsmoleküle zur oralen verabreichung von biologisch aktiven stoffen
AU2019230230B2 (en) 2018-03-08 2025-04-10 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
KR20250174998A (ko) 2018-03-08 2025-12-15 어플라이드 몰레큘라 트랜스포트 인크. 경구 전달용 독소-유래 전달 구조체
CA3150859A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification
US20230125871A1 (en) * 2020-03-18 2023-04-27 Gi Innovation, Inc. Fusion protein preparation comprising il-2 and cd80 proteins
CA3214463A1 (en) * 2021-03-24 2022-09-29 Jcr Pharmaceuticals Co., Ltd. Stable aqueous pharmaceutical composition or freeze-dried pharmaceutical composition

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839314A (en) * 1971-06-29 1974-10-01 Baxter Laboratories Inc Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
US4933179A (en) * 1983-08-22 1990-06-12 Syntex (U.S.A.) Inc. Feline leukemia virus antigen vaccines
DE3406497A1 (de) * 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
US5234683A (en) * 1985-06-18 1993-08-10 Emory University Method of stimulating the immune system
US5182106A (en) * 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5152979A (en) * 1986-05-15 1992-10-06 Emory University Method for treating vascular obstructions caused by abnormal cells
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5071649A (en) * 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
AU1396588A (en) * 1987-02-20 1988-09-14 Emory University Antiinfective compounds and method of use
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
EP1659132A1 (de) * 1987-08-11 2006-05-24 New York University BPI Fragmente
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH02107163A (ja) * 1988-10-15 1990-04-19 Suntory Ltd 新規なゲル状食品の製造方法
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US4997664A (en) * 1989-09-05 1991-03-05 Bryan Foods, Inc. Method for packaging food products
AU9127591A (en) * 1990-12-03 1992-06-25 New York University Biologically active bactericidal/permeability-increasing protein fragments
IE920860A1 (en) * 1991-03-19 1992-09-23 Cytrx Corp Polyoxypropylene/polyoxyethylene copolymers with improved¹biological activity
US5234908A (en) * 1991-04-12 1993-08-10 Creative Biomolecules, Inc. Method of treating gastrointestinal ulcers with platelet derived growth factor
JPH07502642A (ja) * 1991-09-26 1995-03-23 インサイト　ファーマシューティカルズ，インコーポレイテッド 新規な形態のリポ糖結合性タンパク質（ｌｂｐ）
WO1993023434A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
ATE178652T1 (de) * 1992-05-19 1999-04-15 Xoma Corp Verbessertes verfahren zur herstellung von endotoxinbindungsproteinen
JP3946246B2 (ja) * 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性／浸透性増大タンパク質（Ｂａｃｔｅｒｉｃｉｄａｌ／Ｐｅｒｍｅａｂｉｌｉｔｙ Ｉｎｃｒｅａｓｉｎｇ ｐｒｏｔｅｉｎ：ＢＰＩ）及び界面活性剤を含有する医薬組成物
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products

Also Published As

Publication number Publication date
DE69428521T2 (de) 2002-05-23
EP0682524B1 (de) 2001-10-04
EP0682524A1 (de) 1995-11-22
AU695125B2 (en) 1998-08-06
US5955427A (en) 1999-09-21
PT682524E (pt) 2002-03-28
JPH10513433A (ja) 1998-12-22
DE69428521D1 (de) 2001-11-08
WO1994017819A1 (en) 1994-08-18
AU6133094A (en) 1994-08-29
US5488034A (en) 1996-01-30
CA2155005A1 (en) 1994-08-18
US6255284B1 (en) 2001-07-03
HK1014156A1 (en) 1999-09-24
JP2005145986A (ja) 2005-06-09
US5696090A (en) 1997-12-09
CN1163264C (zh) 2004-08-25
JP3946246B2 (ja) 2007-07-18
DK0682524T3 (da) 2002-01-28
CA2155005C (en) 1999-04-06
US6066620A (en) 2000-05-23
CN1127992A (zh) 1996-07-31
ES2164098T3 (es) 2002-02-16

Similar Documents

Publication Publication Date Title
ATE206308T1 (de) Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
DE10199011I2 (de) ASP-B28-Insulinkristalle.
ATE187740T1 (de) Modifizierte proteine und peptide enthaltende pharmazeutische mittel
ES2089011T3 (es) Excipiente lipidico de administracion nasal y aplicacion topica.
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
ATE165100T1 (de) Peptide mit endothelin antagonistischer aktivität, deren herstellung und pharmazeutische zusammensetzungen
IL143633A0 (en) Peptides containing ovarian carcinoma proteins and pharmaceutical compositions and vaccines containing the same
ATE177645T1 (de) Stabilisierte pharmazeutische formulierung, die wachstumshormon und asparagin enthält
ATE411802T1 (de) Kombinationspräparate von 1,4- benzothiepin-1,1- dioxidderivaten mit weiteren wirkstoffen und deren verwendung
ATE281155T1 (de) Medikamentöse verabreichung von proteinen aus polymergemischen
BR0211186A (pt) peptìdeos e uso dos mesmos no escurecimento da pele
DK0973546T3 (da) Stabiliserede formuleringer med human papillomavirus
IT1272252B (it) Formulazioni liquide di interferone beta
CA2071757A1 (en) Implant compositions containing a biologically active protein, peptide or polypeptide
Guigon et al. Inhibitory peptides in hematopoiesis
IL152202A0 (en) Human kcnq5 polypeptide and pharmaceutical compositions containing the same
KR900700079A (ko) 누출방지 리포좀 제제
ATE213953T1 (de) Ein wachstumshormon und leucin enthaltende pharmazeutische formulierung
TR200102265T2 (tr) Anestezi düzenlemesi.
DE69804674D1 (de) Liposomen mit mehrfach verzweigten peptidkonstruktionen zur verwendung gegen hiv
ATE208627T1 (de) Orale zusammensetzungen mit niedrigdosierten zytotoxischen proteinen
ATE239499T1 (de) Protein-disulfid-isomerasen enthaltende pharmazeutische zusammensetzungen
ITMI922332A1 (it) Composizioni farmaceutiche per la somministrazione di paratormone, suoi frammenti biologicamente attivi o peptidi correlati per via rettale.
DE60044468D1 (de) Herstellung von sekretierten polypeptiden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee